Hormones and Cancer
Journal Impact IF - Analysis · Trend · Prediction · Ranking


Journal Impact IF




Journal Impact IF Trend

Related Journals

Popular Journals

Hormones and Cancer

The 2019-2020 Journal Impact IF of Hormones and Cancer is 2.437, which is just updated in 2020.

Hormones and Cancer Impact Factor
Highest IF
Highest Journal Impact IF

The highest Journal Impact IF of Hormones and Cancer is 3.862.

Lowest IF
Lowest Journal Impact IF

The lowest Journal Impact IF of Hormones and Cancer is 0.727.

Total Growth Rate
IF Total Growth Rate

The total growth rate of Hormones and Cancer IF is 235.2%.

Annual Growth Rate
IF Annual Growth Rate

The annual growth rate of Hormones and Cancer IF is 26.1%.

Journal Impact IF Ranking

Subcategory Quartile Rank Percentile
Cancer Research Q3 106/198

Cancer Research 46%

Endocrine and Autonomic Systems Q3 14/24

Endocrine and Autonomic Systems 43%

Oncology Q2 124/331

Oncology 62%

Endocrinology Q2 56/118

Endocrinology 52%

Endocrinology, Diabetes and Metabolism Q2 81/217

Endocrinology, Diabetes and Metabolism 62%

Journal Impact IF Ranking

· In the Cancer Research research field, the Quartile of Hormones and Cancer is Q3. Hormones and Cancer has been ranked #106 over 198 related journals in the Cancer Research research category. The ranking percentile of Hormones and Cancer is around 46% in the field of Cancer Research.
· In the Endocrine and Autonomic Systems research field, the Quartile of Hormones and Cancer is Q3. Hormones and Cancer has been ranked #14 over 24 related journals in the Endocrine and Autonomic Systems research category. The ranking percentile of Hormones and Cancer is around 43% in the field of Endocrine and Autonomic Systems.
· In the Oncology research field, the Quartile of Hormones and Cancer is Q2. Hormones and Cancer has been ranked #124 over 331 related journals in the Oncology research category. The ranking percentile of Hormones and Cancer is around 62% in the field of Oncology.
· In the Endocrinology research field, the Quartile of Hormones and Cancer is Q2. Hormones and Cancer has been ranked #56 over 118 related journals in the Endocrinology research category. The ranking percentile of Hormones and Cancer is around 52% in the field of Endocrinology.
· In the Endocrinology, Diabetes and Metabolism research field, the Quartile of Hormones and Cancer is Q2. Hormones and Cancer has been ranked #81 over 217 related journals in the Endocrinology, Diabetes and Metabolism research category. The ranking percentile of Hormones and Cancer is around 62% in the field of Endocrinology, Diabetes and Metabolism.

Hormones and Cancer Impact Factor 2020-2021 Prediction

Hormones and Cancer Impact Factor Predition System

Hormones and Cancer Impact Factor Prediction System is now online. You can start share your valuable insights with the community.

Predict Check All Preditions
Total Publications
Total Citations

Annual Publication Volume

Annual Citation Record

International Collaboration Trend

Cited Documents Trend

Journal Impact IF History

Year Journal Impact IF
Year Journal Impact IF
2019-2020 2.437
2018-2019 2.239
2017-2018 2.581
2016-2017 3.709
2015-2016 3.167
2014-2015 2.154
2013-2014 3.862
2012-2013 2.797
2011-2012 0.727
Journal Impact IF History

· The 2019-2020 Journal Impact IF of Hormones and Cancer is 2.437
· The 2018-2019 Journal Impact IF of Hormones and Cancer is 2.239
· The 2017-2018 Journal Impact IF of Hormones and Cancer is 2.581
· The 2016-2017 Journal Impact IF of Hormones and Cancer is 3.709
· The 2015-2016 Journal Impact IF of Hormones and Cancer is 3.167
· The 2014-2015 Journal Impact IF of Hormones and Cancer is 2.154
· The 2013-2014 Journal Impact IF of Hormones and Cancer is 3.862
· The 2012-2013 Journal Impact IF of Hormones and Cancer is 2.797
· The 2011-2012 Journal Impact IF of Hormones and Cancer is 0.727

Publications Cites Dataset

Year Publications Citations
Year Publications Citations
2009 1 2
2010 32 13
2011 38 71
2012 23 351
2013 31 556
2014 35 622
2015 30 750
2016 39 699
2017 31 777
2018 41 719
2019 21 764
2020 23 1023
2021 0 83
Publications Cites Dataset

· The Hormones and Cancer has published 1 reports and received 2 citations in 2009.
· The Hormones and Cancer has published 32 reports and received 13 citations in 2010.
· The Hormones and Cancer has published 38 reports and received 71 citations in 2011.
· The Hormones and Cancer has published 23 reports and received 351 citations in 2012.
· The Hormones and Cancer has published 31 reports and received 556 citations in 2013.
· The Hormones and Cancer has published 35 reports and received 622 citations in 2014.
· The Hormones and Cancer has published 30 reports and received 750 citations in 2015.
· The Hormones and Cancer has published 39 reports and received 699 citations in 2016.
· The Hormones and Cancer has published 31 reports and received 777 citations in 2017.
· The Hormones and Cancer has published 41 reports and received 719 citations in 2018.
· The Hormones and Cancer has published 21 reports and received 764 citations in 2019.
· The Hormones and Cancer has published 23 reports and received 1023 citations in 2020.
· The Hormones and Cancer has published 0 reports and received 83 citations in 2021.
· The total publications of Hormones and Cancer is 345.
· The total citations of Hormones and Cancer is 6430.

What is Impact Factor?

The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly average number of citations of articles published in the last two years in a given journal. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factor values are often deemed to be more important, or carry more intrinsic prestige in their respective fields, than those with lower values.

Hormones and Cancer | Academic Accelerator - About the Impact Factor

Impact factor is commonly used to evaluate the relative importance of a journal within its field and to measure the frequency with which the “average article” in a journal has been cited in a particular time period. Journal which publishes more review articles will get highest IFs. Journals with higher IFs believed to be more important than those with lower ones. According to Eugene Garfield “impact simply reflects the ability of the journals and editors to attract the best paper available.” Journal which publishes more review articles will get maximum IFs. The Impact Factor of an academic journal is a scientometric Metric that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a Metric for the relative importance of a journal within its field; journals with higher Impact Factor are often deemed to be more important than those with lower ones. The Hormones and Cancer Impact Factor IF measures the average number of citations received in a particular year (2020) by papers published in the Hormones and Cancer during the two preceding years (2018-2019). Note that 2020 Impact Factor are reported in 2021; they cannot be calculated until all of the 2020 publications have been processed by the indexing agency. New journals, which are indexed from their first published issue, will receive an impact factor after two years of indexing; in this case, the citations to the year prior to Volume 1, and the number of articles published in the year prior to Volume 1, are known zero values. Journals that are indexed starting with a volume other than the first volume will not get an impact factor until they have been indexed for three years. Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. In addition to the 2-year Impact Factor, the 3-year Impact Factor, 4-year Impact Factor, 5-year Impact Factor, Real-Time Impact Factor can provide further insights and factors into the impact of Hormones and Cancer.


The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI). Impact factors are calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson ISI was sold to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.


The impact factor is used to compare different journals within a certain field. The Web of Science indexes more than 11,500 science and social science journals. Journal impact factors are often used to evaluate the merit of individual articles and individual researchers. This use of impact factors was summarised by Hoeffel:

Impact Factor is not a perfect tool to measure the quality of articles but there is nothing better and it has the advantage of already being in existence and is, therefore, a good technique for scientific evaluation. Experience has shown that in each specialty the best journals are those in which it is most difficult to have an article accepted, and these are the journals that have a high impact factor. Most of these journals existed long before the impact factor was devised. The use of impact factor as a measure of quality is widespread because it fits well with the opinion we have in each field of the best journals in our specialty....In conclusion, prestigious journals publish papers of high level. Therefore, their impact factor is high, and not the contrary.

Eugene Garfield

In brief, Impact factors may be used by:
  • Authors to decide where to submit an article for publication.
  • Libraries to make collection development decisions
  • Academic departments to assess academic productivity
  • Academic departments to make decisions on promotion and tenure.
As impact factors are a journal-level metric, rather than an article- or individual-level metric, this use is controversial. Garfield agrees with Hoeffel,but warns about the "misuse in evaluating individuals" because there is "a wide variation [of citations] from article to article within a single journal". Other things to consider about Impact Factors:
  • Many journals do not have an impact factor.
  • The impact factor cannot assess the quality of individual articles. Even if citations were evenly distributed among articles, the impact factor would only measure the interests of other researchers in an article, not its importance and usefulness.
  • Only research articles, technical notes and reviews are “citable” items. Editorials, letters, news items and meeting abstracts are “non-citable items”.
  • Only a small percentage of articles are highly cited and they are found in a small subset of journals. This small proportion accounts for a large percentage of citations.
  • Controversial papers, such as those based on fraudulent data, may be highly cited, distorting the impact factor of a journal.
  • Citation bias may exist. For example, English language resources may be favoured. Authors may cite their own work.
Moreover, informed and careful use of these impact data is essential, and should be based on a thorough understanding of the methodology used to generate impact factors. There are controversial aspects of using impact factors:
  • It is not clear whether the number of times a paper is cited measures its actual quality.
  • Some databases that calculate impact factors fail to incorporate publications including textbooks, handbooks and reference books.
  • Certain disciplines have low numbers of journals and usage. Therefore, one should only compare journals or researchers within the same discipline.
  • Review articles normally are cited more often and therefore can skew results.
  • Self-citing may also skew results.
  • Some resources used to calculate impact factors have inadequate international coverage.
  • Editorial policies can artificially inflate an impact factor.
Impact factors have often been used in advancement and tenure decision-making. Many recognize that this is a coarse tool for such important decisions, and that a multitude of factors should be taken into account in these deliberations. When considering the use of the impact factor (IF), keep these aspects in mind:
  • IF analysis is limited to citations from the journals indexed by the Web of Science/Web of Knowledge. Currently, the Web of Science indexes only 8621 journals across the full breadth of the sciences, and just 3121 in the social sciences.
  • A high IF/citation rate says nothing about the quality -- or even, validity -- of the references being cited. Notorious or even retracted articles often attract a lot of attention, hence a high number of citations. The notority related to the first publication on "cold fusion" is one such example.
  • Journals that publish more "review articles" are often found near the top of the rankings. While not known for publishing new, creative findings, these individual articles tend to be heavily cited.
  • The IF measures the average number of citations to articles in the journal -- given this, a small number of highly-cited articles will skew the figure.
  • It takes several years for new journals to be added to the list of titles indexed by the Web of Science/Web of Knowledge, so these newer titles will be under-represented.
  • It's alleged that journal editors have learned to "game" the system, encouraging authors to cite their works previously published in the same journal.
Comparing Journals Across Disciplines? Not a good idea! Using Impact Factors within a given discipline should only be done with great care, as described above. Using impact factor data to compare journals across disciplines is even more problematic. Here are some of the reasons:
  • Disciplines where older literature is still referenced, such as Chemistry and Mathematics, offer challenges to the methodolgy since older citations (older than two years) are not used to calculate the impact factor for a given journal. (Five-year impact factor analysis, which can be calculated using the Journal Citation Index database, helps smooth out this problem only to some degree.)
  • Different disciplines have different practices regarding tendency to cite larger numbers of references. Higher overall citation rates will bump upward impact factor measurements.
  • Where it's common for large numbers of authors to collaborate on a single paper, such as in Physics, the tendency of authors to cite themselves (and in this case, more authors) will result in increased citation rates.

Pros and Cons of the Impact Factor


  • A vetted, established metric for measuring journal impact within a discipline.
  • Designed to eliminate bias based on journal size and frequency.
  • Individual articles makes an uneven contribution to overall Impact Factor.
  • Impact Factor does not account for certain things, things like context (postive or negative citaion) and intentionality (self-citation).
  • The metric is proprietary to and bound by the contents of the Thomson Reuters database.
  • Citations, on which the Impact Factor is based, count for less than 1% of an article's overall use.


Numerous critiques have been made regarding the use of impact factors. A 2007 study noted that the most fundamental flaw is that impact factors present the mean of data that are not normally distributed, and suggested that it would be more appropriate to present the median of these data. There is also a more general debate on the validity of the impact factor as a measure of journal importance and the effect of policies that editors may adopt to boost their impact factor (perhaps to the detriment of readers and writers). Other criticism focuses on the effect of the impact factor on behavior of scholars, editors and other stakeholders. Others have made more general criticisms, arguing that emphasis on impact factor results from negative influence of neoliberal policies on academia claiming that what is needed is not just replacement of the impact factor with more sophisticated metrics for science publications but also discussion on the social value of research assessment and the growing precariousness of scientific careers in higher education.
Experts stress that there are limitations in using impact factors to evaluate a scholar's work. There are many reasons cited for not relying on impact factor alone to evaluate the output of a particular individual. Among these are the following:

  • A single factor is not sufficient for evaluating an author's work.
  • Journal values are meaningless unless compared within the same discipline. Impact factors vary among disciplines.
  • The impact factor was originally devised to show the impact of a specific journal, not a specific scholar. The quality and impact of the author's work may extend beyond the impact of a particular journal.
According to Jim Testa, a researcher for ThomsonReuters Scientific, the most widespread misuse of the Impact Factor is to evaluate the work of an individual author (instead of a journal). "To say that because a researcher is publishing in a certain journal, he or she is more influential or deserves more credit is not necessarily true. There are many other variables to consider." (interview 6/26/2008 in Thomson Reuters blog entry)

Hormones and Cancer
Journal Profile


Hormones and Cancer is a unique multidisciplinary translational journal featuring basic science, pre-clinical, epidemiological, and clinical research papers. It covers all aspects of the interface of Endocrinology and Oncology. Thus, the journal covers two main areas of research: Endocrine tumors (benign & malignant tumors of hormone secreting endocrine organs) and the effects of hormones on any type of tumor. We welcome all types of studies related to these fields, but our particular attention is on translational aspects of research. In addition to basic, pre-clinical, and epidemiological studies, we encourage submission of clinical studies including those that comprise small series of tumors in rare endocrine neoplasias and/or negative or confirmatory results provided that they significantly enhance our understanding of endocrine aspects of oncology. The journal does not publish case studies. None

Highly Cited Keywords


The ISSN of Hormones and Cancer is 1868-8497 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

ISSN (Online)
ISSN (Online)

The ISSN (Online) of Hormones and Cancer is 1868-8500 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

Springer US

Hormones and Cancer is published by Springer US .

Publication Frequency
Publication Frequency

Hormones and Cancer publishes reports Other .

2010 - Present

The Publication History of Hormones and Cancer covers 2010 - Present .

Open Access
Open Access

Hormones and Cancer is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. Anyone who wants to use the articles in any way must obtain permission from the publishers.

Publication Fee
Publication Fee

There is no publication fee for submiting manuscript to Hormones and Cancer. Hormones and Cancer is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles.


The language of Hormones and Cancer is English .

United States

The publisher of Hormones and Cancer is Springer US , which locates in United States .

Selected Articles

Full Title Authors
Full Title Authors
RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer—a Review Gowri Palanissami · Solomon F. D. Paul · Solomon F. D. Paul
Fasting Blood Glucose Level in Locally Advanced Non-Small Cell Lung Cancer: a New Prognostic Factor? Esra Korkmaz Kirakli · Ufuk Yilmaz · Hasan Yilmaz · Berna Komurcuoglu · Berna Komurcuoglu
The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer Vladimir Djedovic · Yoo-Young Lee · Alexandra Kollara · Taymaa May · Theodore J. Brown · Theodore J. Brown
Circulating Hormones and Mammographic Density in Premenopausal Women Kimberly A. Bertrand · A. Heather Eliassen · A. Heather Eliassen · Susan E. Hankinson · Susan E. Hankinson · Susan E. Hankinson · Bernard Rosner · Bernard Rosner · Rulla M. Tamimi · Rulla M. Tamimi · Rulla M. Tamimi
Adiponectin, Leptin, and Insulin-Pathway Receptors as Endometrial Cancer Subtyping Markers Evan L. Busch · Evan L. Busch · Marta Crous-Bou · Jennifer Prescott · Michael J. Downing · Bernard Rosner · Bernard Rosner · George L. Mutter · Immaculata De Vivo · Immaculata De Vivo · Immaculata De Vivo
BRAF -Oncogene-Induced Senescence and the Role of Thyroid-Stimulating Hormone Signaling in the Progression of Papillary Thyroid Carcinoma F. I. Moulana · Aah Priyani · M. V. C. De Silva · R. S. Dassanayake · R. S. Dassanayake
Statin Use and Breast Cancer Prognosis in Black and White Women Amanda Leiter · Nina A. Bickell · Derek LeRoith · Anupma Nayak · Sheldon Feldman · Neil Friedman · Alison Estabrook · Tari A. King · Kezhen Fei · Rebeca Franco · Emily Jane Gallagher · Emily Jane Gallagher
Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors Delphine Vezzosi · Christine Do Cao · S. Hescot · S. Hescot · Jérôme Bertherat · Magali Haissaguerre · Vanina Bongard · D. Drui · Christelle De La Fouchardiere · F. Illouz · Françoise Borson-Chazot · Bodale Djobo · A. Berdelou · Antoine Tabarin · Martin Schlumberger · Claire Briet · Philippe Caron · Sophie Leboulleux · Rossella Libé · Eric Baudin · Eric Baudin · Eric Baudin
Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells Patricia Mjønes · Ivar S. Nordrum · Øystein Sørdal · Liv Sagatun · Reidar Fossmark · Arne K. Sandvik · Helge L. Waldum · Helge L. Waldum
Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer Ana Sahores · Virginia Figueroa · Maria May · Marcos Liguori · Adrián Rubstein · Cynthia Fuentes · Britta M. Jacobsen · Andrés Elía · Gonzalo Ricardo Sequeira · Michelle M. Álvarez · Pedro Gonzalez · Hugo Gass · Stephen M. Hewitt · Alfredo A. Molinolo · Claudia Lanari · Caroline A. Lamb · Caroline A. Lamb
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment Raffaele Hellweg · Raffaele Hellweg · Ashley Mooneyham · Zenas Chang · M. Shetty · Edith Emmings · Yoshie Iizuka · Christopher M. Clark · Timothy K. Starr · Juan H. Abrahante · Florian Schütz · Gottfried E. Konecny · Peter A. Argenta · Martina Bazzaro · Martina Bazzaro
Androgen Receptor and Ki67 Expression and Survival Outcomes in Non-small Cell Lung Cancer Laurel Grant · Shantanu Banerji · Leigh C. Murphy · David E. Dawe · Craig Harlos · Yvonne Myal · Zoann Nugent · Anne Blanchard · Carla Penner · Gefei Qing · Marshall W. Pitz · Marshall W. Pitz
O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer Gloria M. Trinca · Merit L. Goodman · Evangelia K. Papachristou · Clive D’Santos · Prabhakar Chalise · Rashna Madan · Chad Slawson · Christy R. Hagan · Christy R. Hagan
The Influence of Menopausal Hormone Therapy and Potential Lifestyle Interactions in Female Cancer Development—a Population-Based Prospective Study Marianne Holm · Anja Olsen · Cecilie Kyrø · Kim Overvad · Niels Kroman · Anne Tjønneland · Anne Tjønneland
Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome Zongping Chen · Jichun Deng · Yong Yan · Min Li · Chanjuan Chen · Chao Chen · Sicong Zhao · Tao Song · Tong Liu · Xin Wen · Yuhong Yao · Yuhong Yao
The Flavonoid Apigenin Is a Progesterone Receptor Modulator with In Vivo Activity in the Uterus Matthew Dean · Julia R. Austin · Ren Jinhong · Michael E. Johnson · Daniel D. Lantvit · Joanna E. Burdette · Joanna E. Burdette
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer Sasha M. Pejerrey · Derek Dustin · Jin-Ah Kim · Guowei Gu · Yassine Rechoum · Suzanne A. W. Fuqua · Suzanne A. W. Fuqua
The Impact of Hormonal Contraceptives on Breast Cancer Pathology Jesse A. Dorchak · Sifat Maria · Joseph L. Guarinoni · Anette Duensing · Stella Somiari · Jane E. Cavanaugh · Brenda Deyarmin · Hai Hu · Joji Iida · Craig D. Shriver · Paula A. Witt-Enderby · Paula A. Witt-Enderby
Adiponectin Reverses the Proliferative Effects of Estradiol and IGF-1 in Human Epithelial Ovarian Cancer Cells by Downregulating the Expression of Their Receptors Marta Hoffmann · Justyna Gogola · Anna Ptak · Anna Ptak
Urban Neighborhood and Residential Factors Associated with Breast Cancer in African American Women: a Systematic Review Brandi Patrice Smith · Zeynep Madak-Erdogan · Zeynep Madak-Erdogan
Adiposity Results in Metabolic and Inflammation Differences in Premenopausal and Postmenopausal Women Consistent with the Difference in Breast Cancer Risk Hong Zhao · Jun Wang · D. Fang · Oukseub Lee · Robert T. Chatterton · Vered Stearns · Seema A. Khan · Serdar E. Bulun · Serdar E. Bulun
Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer Jessica L. Christenson · Jane B. Trepel · Haythem Y. Ali · Sunmin Lee · Joel R. Eisner · Edwina S. Baskin-Bey · Anthony Elias · Jennifer K. Richer · Jennifer K. Richer
The Interplay Between Epithelial-Mesenchymal Transition (EMT) and the Thyroid Hormones-αvβ3 Axis in Ovarian Cancer Chen Weingarten · Chen Weingarten · Yonatan Jenudi · Yonatan Jenudi · Rami Yair Tshuva · Dotan Moskovich · Dotan Moskovich · Adi Alfandari · Adi Alfandari · Aleck Hercbergs · Paul J. Davis · Martin Ellis · Martin Ellis · Osnat Ashur-Fabian · Osnat Ashur-Fabian · Osnat Ashur-Fabian
Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats Bianca Facchim Gonçalves · Silvana G.P. Campos · Wagner José Fávaro · Joyce Zalotti Brandt · Cristiane Figueiredo Pinho · Luis A. Justulin · Sebastião Roberto Taboga · Wellerson R. Scarano · Wellerson R. Scarano
Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers André Wendindondé Nana · Szu Yuan Wu · Yu Chen Sh Yang · Yu Tang Chin · Tsai Mu Cheng · Yih Ho · Wen Shan Li · Yu Min Liao · Yi Ru Chen · Ya Jung Shih · Yun Ru Liu · Jens Z. Pedersen · Sandra Incerpi · Aleck Hercbergs · Leroy F. Liu · Jacqueline Whang-Peng · Paul J. Davis · Hung Yun Lin · Hung Yun Lin
The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer Courtney L. Andersen · M.M. Boisen · Matthew J. Sikora · Tianzhou Ma · George C. Tseng · Swati Suryawanshi · Anda M. Vlad · Esther Elishaev · Robert P. Edwards · Steffi Oesterreich · Steffi Oesterreich
Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results Yann Neuzillet · Jean-Pierre Raynaud · Jean-François Dreyfus · Camelia Radulescu · Mathieu Rouanne · Marc P. Schneider · Sylvie Krish · Morgan Rouprêt · Sarah Drouin · Eva Comperat · Marc Galiano · Xavier Cathelineau · Pierre Validire · Vincent Molinié · Jean Fiet · Franck Giton · Thierry Lebret · Henry Botto · Henry Botto
The Importance of CYP19A1 in Estrogen Receptor-Positive Cholangiocarcinoma Waleeporn Kaewlert · Chadamas Sakonsinsiri · Nisana Namwat · Kanlayanee Sawanyawisuth · Piti Ungarreevittaya · Narong Khuntikeo · Napat Armartmuntree · Raynoo Thanan · Raynoo Thanan
Familial Cancer Clustering in Patients with Prolactinoma Sandra Pekic · Ivan Soldatovic · Dragana Miljic · Marko Stojanovic · Mirjana Doknic · Milan Petakov · Vera Popovic · Vera Popovic
Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells Yuzhe Yang · Jie Ying Chan · Nuri A. Temiz · Douglas Yee · Douglas Yee
Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation Tung-Cheng Chang · Yu-Tang Chin · André Wendindondé Nana · Shwu-Huey Wang · Yu-Min Liao · Yi-Ru Chen · Ya-Jung Shih · Chun A. Changou · Yu-Chen Sh Yang · Kuan Wang · Jacqueline Whang-Peng · Liang-Shun Wang · Steven C. Stain · Ai Shih · Hung-Yun Lin · Hung-Yun Lin · Chih-Hsiung Wu · Paul J. Davis · Paul J. Davis · Paul J. Davis
Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models Won Gu Kim · Won Gu Kim · Sheue-yann Cheng · Sheue-yann Cheng
Diagnostic Performance of F-18 Fluorocholine PET/CT for Parathyroid Localization in Hyperparathyroidism: a Systematic Review and Meta-Analysis Seong-Jang Kim · Sang-Woo Lee · Shin Young Jeong · Kyoungjune Pak · Keunyoung Kim · Keunyoung Kim
Neck Ultrasound in Patients with Follicular Thyroid Carcinoma Konstantinos Segkos · Kyle Porter · Leigha Senter · Matthew D. Ringel · Fadi Nabhan · Fadi Nabhan
Mammographic Density and Circulating Sex Hormones: a Cross-Sectional Study in Postmenopausal Korean Women Kayoung Lee · Jung Eun Yoo · Tuong L. Nguyen · John L. Hopper · Yun-Mi Song · Yun-Mi Song
Lower Circulating Androgens Are Associated with Overall Cancer Risk and Prostate Cancer Risk in Men Aged 25–84 Years from the Busselton Health Study Yi X. Chan · Matthew Knuiman · Mark L. Divitini · David J. Handelsman · John Beilby · Bu B. Yeap · Bu B. Yeap
Impact of Gender and Age on the Prognosis of Differentiated Thyroid Carcinoma: a Retrospective Analysis Based on SEER Dan Zhang · Jianing Tang · Deguang Kong · Qiuxia Cui · Kun Wang · Yan Gong · Gaosong Wu · Gaosong Wu
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer Andrea Friesenhengst · Tamara Pribitzer-Winner · Heidi Miedl · Katharina Pröstling · Martin Schreiber · Martin Schreiber
Type 1 IGF Receptor Localization in Paediatric Gliomas: Significant Association with WHO Grading and Clinical Outcome Florencia Clément · Ayelen Martin · Marcela Venara · María de Luján Calcagno · Cecilia Mathó · Silvana Maglio · Mercedes García Lombardi · Ignacio Bergadá · Patricia Pennisi · Patricia Pennisi
Thyroid Hormone Promotes β-Catenin Activation and Cell Proliferation in Colorectal Cancer Yee Shin Lee · Yu Tang Chin · Ya Jung Shih · André Wendindondé Nana · Yi Ru Chen · Han-Chung Wu · Yu Chen S.H. Yang · Hung Yun Lin · Paul J. Davis · Paul J. Davis · Paul J. Davis
Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis Zhiyu Li · Qi Wu · Junlong Song · Yimin Zhang · Shan Zhu · Shengrong Sun · Shengrong Sun
Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application Christos Bikis · Theodora Tzanavari · Krystallenia I. Alexandraki · Stamatios Theocharis · Stamatios Theocharis
Thyroid Hormone in the Clinic and Breast Cancer Aleck Hercbergs · Shaker A. Mousa · Matthew C. Leinung · Hung Yun Lin · Paul J. Davis · Paul J. Davis
Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro Ashraf Khalil · Mark J. Jameson · Mark J. Jameson
Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer Wenwen Lu · Benita S. Katzenellenbogen · Benita S. Katzenellenbogen
Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts Shawna B. Matthews · Carol A. Sartorius · Carol A. Sartorius
The Complex Biology of the Aryl Hydrocarbon Receptor and Its Role in the Pituitary Gland Robert Formosa · Josanne Vassallo · Josanne Vassallo · Josanne Vassallo
Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients J. Hadoux · M. Terroir · S. Leboulleux · F. Deschamps · Abir Al Ghuzlan · S. Hescot · Lambros Tselikas · Isabelle Borget · C. Caramella · D. Deandreis · D. Goere · Thierry de Baere · Martin Schlumberger · E. Baudin · E. Baudin
miR-15b Inhibits the Progression of Glioblastoma Cells Through Targeting Insulin-like Growth Factor Receptor 1 Jian Wang · Huaqiang Liu · Lin Tian · Fachen Wang · Liangbo Han · Wei Zhang · Yunan Bai · Yunan Bai
Thyroid Hormone Controls Breast Cancer Cell Movement via Integrin αV/β3/SRC/FAK/PI3-Kinases Marina Inés Flamini · Ivonne Denise Uzair · Gisela E. Pennacchio · Flavia Judith Neira · Joselina Magali Mondaca · Fernando Darío Cuello-Carrión · Graciela A. Jahn · Tommaso Simoncini · Angel Matías Sanchez · Angel Matías Sanchez
Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer Krassimira Todorova · Metodi V. Metodiev · Gergana Metodieva · Milcho Mincheff · Nelson Fernandez · Soren Hayrabedyan · Soren Hayrabedyan
Effects of Long-Term Vitamin D Supplementation on Regression and Metabolic Status of Cervical Intraepithelial Neoplasia: a Randomized, Double-Blind, Placebo-Controlled Trial Zahra Vahedpoor · Mehri Jamilian · Fereshteh Bahmani · Esmat Aghadavod · Maryam Karamali · Maryam Kashanian · Zatollah Asemi · Zatollah Asemi
Over-Expression of Activin-βC Is Associated with Murine and Human Prostate Disease Edward Ottley · Karen L. Reader · Kailun Lee · Francesco Elia Marino · Helen D. Nicholson · Gail P. Risbridger · Elspeth Gold · Elspeth Gold
Parity and Risk of Thyroid Cancer: a Population-Based Study in Lithuania L. Zabuliene · Domantas Jasilionis · Domantas Jasilionis · E. Miseikyte-Kaubriene · E. Miseikyte-Kaubriene · Rimantas Stukas · A. Kaceniene · Giedre Smailyte · Giedre Smailyte · Giedre Smailyte
Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer Helena Pópulo · Bruno Nunes · Bruno Nunes · Cristina Sampaio · Rui Batista · Marta Pinto · Tiago Bordeira Gaspar · Leandro Miranda-Alves · Leandro Miranda-Alves · Ren Zhi Cai · Xian Yang Zhang · Andrew V. Schally · Manuel Sobrinho-Simões · Paula Soares · Paula Soares
Expression of Genes for Methylxanthine Pathway-Associated Enzymes Accompanied by Sex Steroid Receptor Status Impacts Breast Carcinoma Progression James L. Wittliff · Seth B. Sereff · Michael W. Daniels · Michael W. Daniels
Risk of Gonadoblastoma Development in Patients with Turner Syndrome with Cryptic Y Chromosome Material Ahreum Kwon · Sei Eun Hyun · Mo Kyung Jung · Hyun Wook Chae · Woo Jung Lee · Tae Hyuk Kim · Duk Hee Kim · Ho-Seong Kim · Ho-Seong Kim
Clinical and Metabolic Response to Vitamin D Supplementation in Endometrial Hyperplasia: a Randomized, Double-Blind, Placebo-Controlled Trial Zohreh Tabassi · Sedigheh Bagheri · Mansooreh Samimi · Hamid Reza Gilasi · Fereshteh Bahmani · Maryam Chamani · Zatollah Asemi · Zatollah Asemi
Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma Maximilian C. Kriegmair · Philipp Mandel · Stefan Porubsky · Julia Dürr · Nina Huck · Philipp Nuhn · Daniel Pfalzgraf · Maurice Stephan Michel · Nina Wagener · Nina Wagener
Bisphenol A Induces Sox2 in ER+ Breast Cancer Stem-Like Cells M. Angeles Lillo · Cydney Nichols · Tiffany N. Seagroves · Gustavo A. Miranda-Carboni · Susan A. Krum · Susan A. Krum
Aryl Hydrocarbon Receptor–Interacting Protein (AIP) N-Terminus Gene Mutations Identified in Pituitary Adenoma Patients Alter Protein Stability and Function Robert Formosa · Josanne Vassallo · Josanne Vassallo · Josanne Vassallo
Higher Dihydrotestosterone Is Associated with the Incidence of Lung Cancer in Older Men Yi X. Chan · Yi X. Chan · Helman Alfonso · S. A. Paul Chubb · S. A. Paul Chubb · David J. Handelsman · P. Gerry Fegan · Graeme J. Hankey · Graeme J. Hankey · Jonathan Golledge · Jonathan Golledge · Leon Flicker · Bu B. Yeap · Bu B. Yeap · Bu B. Yeap
MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression Jessica L. Christenson · Kiel T. Butterfield · Nicole S. Spoelstra · John D. Norris · Jatinder S. Josan · Julie A. Pollock · Donald P. McDonnell · Benita S. Katzenellenbogen · John A. Katzenellenbogen · Jennifer K. Richer · Jennifer K. Richer
Editorial: Towards Improving the Science of Hormones and Cancer Carol A. Lange · Carol A. Lange
Perinatal Exposure to Bisphenol A or Diethylstilbestrol Increases the Susceptibility to Develop Mammary Gland Lesions After Estrogen Replacement Therapy in Middle-Aged Rats Ayelen L. Gomez · Melisa B. Delconte · Gabriela A. Altamirano · Lucía Vigezzi · Verónica L. Bosquiazzo · Luis Fernando Barbisan · Jorge G. Ramos · Enrique H. Luque · Mónica Muñoz-de-Toro · Laura Kass · Laura Kass
A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy Irida Kastrati · Marton I. Siklos · Svitlana Brovkovych · Gregory R. J. Thatcher · Jonna Frasor · Jonna Frasor
Role of 20-Hydroxyeicosatetraenoic Acid (20-HETE) in Androgen-Mediated Cell Viability in Prostate Cancer Cells Cecilia Colombero · Daniela L. Papademetrio · Paula Alejandra Sacca · Eduardo Mormandi · Elida Alvarez · Susana Nowicki · Susana Nowicki
Nanoparticulate Tetrac Inhibits Growth and Vascularity of Glioblastoma Xenografts Thangirala Sudha · Dhruba J. Bharali · Stewart Sell · Noureldien H. E. Darwish · Paul J. Davis · Paul J. Davis · Shaker A. Mousa · Shaker A. Mousa
Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps Reetobrata Basu · Nicholas Baumgaertel · Shiyong Wu · John J. Kopchick · John J. Kopchick · John J. Kopchick
Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6 Hirofumi Ando · Tsutomu Miyamoto · Hiroyasu Kashima · Shotaro Higuchi · Koichi Ida · David Hamisi Mvunta · Tanri Shiozawa · Tanri Shiozawa
Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years Michelle L. Baglia · Kathleen E. Malone · Mei-Tzu C. Tang · Christopher I. Li · Christopher I. Li
Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation Dedra H. Fagan · Lynsey M. Fettig · Svetlana Avdulov · Heather Beckwith · Mark Peterson · Yen Yi Ho · Fan Wang · Vitaly A. Polunovsky · Douglas Yee · Douglas Yee
The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer Elizabeth A. Wellberg · L. Allyson Checkley · Erin D. Giles · Stevi Johnson · Robera Oljira · Reema Wahdan-Alaswad · Rebecca M. Foright · Greg Dooley · Susan M. Edgerton · Sonali Jindal · Ginger C. Johnson · Jennifer K. Richer · Peter Kabos · Ann D. Thor · Pepper Schedin · Paul S. MacLean · Steven M. Anderson · Steven M. Anderson
Maternal Resveratrol Treatment Reduces the Risk of Mammary Carcinogenesis in Female Offspring Prenatally Exposure to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Tássia C. de Lima e Silva · Lívia Teresa R. Silveira · Mariana F. Fragoso · Flávia Regina Moraes da Silva · Meire França Martinez · Joyce R. Zapaterini · Odair H. G. Diniz · Wellerson R. Scarano · Luis Fernando Barbisan · Luis Fernando Barbisan
Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas Shiko Asai · Takuyuki Katabami · Mika Tsuiki · Yasushi Tanaka · Mitsuhide Naruse · Mitsuhide Naruse
5th International ACC Symposium Barbra S. Miller · Barbra S. Miller
CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy Huiying Sun · Huiying Sun · Sanjay N. Mediwala · Sanjay N. Mediwala · Adam T. Szafran · Michael A. Mancini · Marco Marcelli · Marco Marcelli · Marco Marcelli
The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer Amy E. Baek · Erik R. Nelson · Erik R. Nelson
Nipple Aspirate Fluid Hormone Concentrations and Breast Cancer Risk Robert T. Chatterton · Richard Heinz · Richard Heinz · Richard Heinz · Angela J. Fought · David Ivancic · Claire Shappell · Claire Shappell · Subhashini Allu · Susan M. Gapstur · Denise M. Scholtens · Peter H. Gann · Peter H. Gann · Seema A. Khan · Seema A. Khan
TERT Promoter Mutations in Thyroid Cancer Ali S. Alzahrani · Rawan Alsaadi · Avaniyapuram Kannan Murugan · Bakr Bin Sadiq · Bakr Bin Sadiq
Bisphenol A (BPA) Exposure In Utero Leads to Immunoregulatory Cytokine Dysregulation in the Mouse Mammary Gland: A Potential Mechanism Programming Breast Cancer Risk Catha Fischer · Ramanaiah Mamillapalli · Laura G. Goetz · Elisa Jorgenson · Ysabel Ilagan · Hugh S. Taylor · Hugh S. Taylor
The Effect of Implementing Gene Expression Classifier on Outcomes of Thyroid Nodules with Indeterminate Cytology Jithma P. Abeykoon · Luke Mueller · Frank Dong · Ashish V. Chintakuntlawar · Jonas Paludo · Rami Mortada · Rami Mortada
Protein Biomarkers for Breast Cancer Risk Are Specifically Correlated with Local Steroid Hormones in Nipple Aspirate Fluid Ali Shidfar · Tolulope Fatokun · David Ivancic · Robert T. Chatterton · Seema A. Khan · Jun Wang · Jun Wang
5th International ACC Symposium: An Outlook to Current and Future Research on the Biology of Adrenocortical Carcinoma: Diagnostic and Therapeutic Applications Enzo Lalli · Enzo Lalli · Hironobu Sasano · Hironobu Sasano
Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B ∼ FIT Cohort Cher M. Dallal · Cher M. Dallal · James V. Lacey · Ruth M. Pfeiffer · Douglas C. Bauer · Douglas C. Bauer · Roni T. Falk · Diana S. M. Buist · Jane A. Cauley · Trisha F. Hue · Andrea Z. LaCroix · Jeffrey A. Tice · Timothy D. Veenstra · Xia Xu · Louise A. Brinton · Louise A. Brinton
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma Ana O. Hoff · Alfredo Berruti · Alfredo Berruti
5th International ACC Symposium: Introduction Gary D. Hammer · Gary D. Hammer
Alcohol Consumption and Urinary Estrogens and Estrogen Metabolites in Premenopausal Women Terryl J. Hartman · Julia S. Sisti · Julia S. Sisti · Susan E. Hankinson · Susan E. Hankinson · Susan E. Hankinson · Xia Xu · A. Heather Eliassen · A. Heather Eliassen · Regina G. Ziegler · Regina G. Ziegler
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer Christopher Foley · Nicholas Mitsiades · Nicholas Mitsiades
5th International ACC Symposium: Surgical Considerations in the Treatment of Adrenocortical Carcinoma: 5th International ACC Symposium Session: Who, When and What Combination? Barbra S. Miller · Barbra S. Miller
Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study Tess V. Clendenen · Kathryn Hertzmark · Karen L. Koenig · Eva Lundin · Sabina Rinaldi · Theron Johnson · Vittorio Krogh · Göran Hallmans · Annika Idahl · Annekatrin Lukanova · Anne Zeleniuch-Jacquotte · Anne Zeleniuch-Jacquotte
5th International ACC Symposium: The New Genetics of Benign Adrenocortical Neoplasia: Hyperplasias, Adenomas, and Their Implications for Progression into Cancer Lawrence S. Kirschner · Constantine A. Stratakis · Constantine A. Stratakis
The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer Cameron P. Capper · James M. Rae · Richard J. Auchus · Richard J. Auchus
Development of Metabolic Syndrome Associated to Cancer Therapy: Review Stephania Casco · Elena Soto-Vega · Elena Soto-Vega
Patient-Derived Prostate Cancer: from Basic Science to the Clinic Gail P. Risbridger · Renea A. Taylor · Renea A. Taylor
Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells Matthias Kroiss · Silviu Sbiera · Sabine Kendl · Max Kurlbaum · Martin Fassnacht · Martin Fassnacht
Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice Dannielle Upton · Kirsty A. Walters · Rachel E. Allavena · Mark Jimenez · Reena Desai · David J. Handelsman · Charles M. Allan · Charles M. Allan
Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling Assumpta C. Nwaneri · Lucien McBeth · Terry D. Hinds · Terry D. Hinds
Synchronous vs. Metachronous Metastases in Adrenocortical Carcinoma: an Analysis of the Dutch Adrenal Network M. H. T. Ettaieb · Jakob Duker · Richard A. Feelders · Eleonora P. M. Corssmit · C. W. Menke-van der Houven van Oordt · H.J.L.M. Timmers · Michael Kerstens · J. W. Wilmink · Pierre Zelissen · Bas Havekes · Harm R. Haak · Harm R. Haak
Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential Brenna M. Zimmer · Michelle E. Howell · Qin Wei · Linlin Ma · Trevor Romsdahl · Eileen Loughman · Jonathan E. Markham · Javier Seravalli · Joseph J. Barycki · Melanie A. Simpson · Melanie A. Simpson
5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications Sarika N. Rao · Mouhammed Amir Habra · Mouhammed Amir Habra
5th International ACC Symposium: Imaging for Diagnosis and Surveillance of Adrenal Tumors—New Advances and Reviews of Old Concepts Stefanie Hahner · Elaine M. Caoili · Tobias Else · Tobias Else
Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression Ailin Zhang · Jiawei Zhang · Stephen R. Plymate · Elahe A. Mostaghel · Elahe A. Mostaghel
Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide Matthias Kroiss · Timo Deutschbein · Wiebke Schlötelburg · Cristina L. Ronchi · Bruno Neu · Hans-Helge Müller · Marcus Quinkler · Stefanie Hahner · Anke Heidemeier · Martin Fassnacht · Martin Fassnacht
5th International ACC Symposium: Hereditary Predisposition to Childhood ACC and the Associated Molecular Phenotype: 5th International ACC Symposium Session: Not Just for Kids! Tobias Else · Carlos Rodriguez-Galindo · Carlos Rodriguez-Galindo
5th International ACC Symposium: Classification of Adrenocortical Cancers from Pathology to Integrated Genomics: Real Advances or Lost in Translation? Ronald E. de Krijger · Jérôme Bertherat · Jérôme Bertherat
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer Abena S. Agyeman · Wesley J. Jun · David A. Proia · Caroline R. Kim · Maxwell N. Skor · Masha Kocherginsky · Suzanne D. Conzen · Suzanne D. Conzen
Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy Hannah Oh · Zeina G. Khodr · Mark E. Sherman · Maya Palakal · Ruth M. Pfeiffer · Laura Linville · Berta M. Geller · Pamela M. Vacek · Donald L. Weaver · Rachael E. Chicoine · Roni T. Falk · Hisani N. Horne · Daphne Papathomas · Deesha A. Patel · Jackie Xiang · Xia Xu · Timothy D. Veenstra · Stephen M. Hewitt · John A. Shepherd · Louise A. Brinton · Jonine D. Figueroa · Jonine D. Figueroa · Gretchen L. Gierach · Gretchen L. Gierach
Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer Handoo Rhee · Handoo Rhee · Ian Vela · Ian Vela · Eric Chung · Eric Chung · Eric Chung
Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model Nathalie Esber · Clément Cherbonnier · Michèle Resche-Rigon · Abdallah Hamze · Mouad Alami · Jérôme Fagart · Hugues Loosfelt · Marc Lombès · Nathalie Chabbert-Buffet · Nathalie Chabbert-Buffet
Clinical Features, Treatments, and Outcomes of Patients with Thymic Carcinoids and Multiple Endocrine Neoplasia Type 1 Syndrome at MD Anderson Cancer Center Ioannis Christakis · Wei Qiu · Wei Qiu · Angelica M. Silva Figueroa · Samuel M. Hyde · Gilbert J. Cote · Naifa L. Busaidy · Michelle A. Williams · Elizabeth G. Grubbs · Jeffrey E. Lee · Nancy D. Perrier · Nancy D. Perrier
Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical Carcinoma L. I. Velikanova · Z. R. Shafigullina · A. A. Lisitsin · N. V. Vorokhobina · K. Grigoryan · E. A. Kukhianidze · E. G. Strelnikova · N. S. Krivokhizhina · L. M. Krasnov · E. A. Fedorov · I. V. Sablin · A. L. Moskvin · E. A. Bessonova · E. A. Bessonova
pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer Yarchoan M · Ma C · Andrea B. Troxel · Stephen Stopenski · Waixing Tang · Waixing Tang · Aaron Benjamin Cohen · Pappas-Paxinos M · Johnson Ba rd · Chen Ey · Feldman · Marcia S. Brose · Marcia S. Brose

Fasting Blood Glucose Level in Locally Advanced Non-Small Cell Lung Cancer: a New Prognostic Factor?
Hormones and Cancer | 2018
Esra Korkmaz Kirakli · Ufuk Yilmaz · Hasan Yilmaz · Berna Komurcuoglu · Berna Komurcuoglu
The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer
Hormones and Cancer | 2018
Vladimir Djedovic · Yoo-Young Lee · Alexandra Kollara · Taymaa May · Theodore J. Brown · Theodore J. Brown
Circulating Hormones and Mammographic Density in Premenopausal Women
Hormones and Cancer | 2018
Kimberly A. Bertrand · A. Heather Eliassen · A. Heather Eliassen · Susan E. Hankinson · Susan E. Hankinson · Susan E. Hankinson · Bernard Rosner · Bernard Rosner · Rulla M. Tamimi · Rulla M. Tamimi · Rulla M. Tamimi
Adiponectin, Leptin, and Insulin-Pathway Receptors as Endometrial Cancer Subtyping Markers
Hormones and Cancer | 2018
Evan L. Busch · Evan L. Busch · Marta Crous-Bou · Jennifer Prescott · Michael J. Downing · Bernard Rosner · Bernard Rosner · George L. Mutter · Immaculata De Vivo · Immaculata De Vivo · Immaculata De Vivo